LumiThera Develops Treatments for Vision Loss from Macular Degeneration

A low-level light treatment called photobiomodulation may be a future treatment for macular degeneration. A company called LumiThera is developing devices for treating vision loss. The devices expose the eye to low-level laser light or light emitting diodes to stimulate cellular function. This is called low level light therapy (LLLT). It is distinct from surgical or aesthetic laser treatments, which destroy tissue.

Visible or near infrared light (NIR) light is produced by a laser or a non-coherent light source. This therapy is in wide use by chiropractors, physiotherapists and sports medicine professionals to treat conditions in many parts of the body.

Focusing specifically on the application of LLLT to counteract vision loss, LumiThera’s website includes research in this area. For example, they link to a case-study of how LLLT improved vision for a patient with retinitis pigmentosa.¹

Oxidative stress is believed to contribute to vision loss due to eye disease. The cells in the retina need a large amount of energy. Low levels of Adenosine Triphosphate (ATP), which gives the cells energy, may contribute to several eye diseases such as Macular Degeneration and Retinitis Pigmentosa. LLLT stimulates ATP production. Cumulative oxidative stress and impaired ATP functioning are common effects of ageing; therefore, the elderly are especially likely to suffer from eye disease.

LumiThera’s technology may prove to counteract the deleterious effects of several serious eye diseases.

Microcurrent Stimulation helps stimulate energy production (ATP) in the retina, improve circulation & reduce waste build-up.

Learn about support for & prevention of macular degeneration.